Favorable outcomes and reduced toxicity with a novel vinblastine-based non-high dose methotrexate (HDMTX) regimen (modified MCP-842) in pediatric anaplastic large cell lymphoma (ALCL): experience from India

References

• Alessandri AJ, Pritchard SL, Schultz KR, et al. A population-based study of pediatric anaplastic large cell lymphoma. Cancer. 2002;94(6):1830–1835.
   PubMed Web of Science ®Google Scholar
• Delsol G, Al Saati T, Gatter KC, et al. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis. Am J Pathol. 1988;130(1):59–70.
   PubMed Web of Science ®Google Scholar
• Brugières L, Le Deley MC, Rosolen A, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009;27(6):897–903.
   PubMed Web of Science ®Google Scholar
• Prokoph N, Larose H, Lim MS, et al. Treatment options for paediatric anaplastic large cell lymphoma (ALCL): current standard and beyond. Cancers. 2018;10(4):99.
   PubMed Web of Science ®Google Scholar
• Reiter A, Schrappe M, Tiemann M, et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol. 1994;12(5):899–908.
   PubMed Web of Science ®Google Scholar
• Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood. 2001;97(12):3699–3706.
   PubMed Web of Science ®Google Scholar
• Williams DM, Hobson R, Imeson J, et al. Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children’s Cancer Study Group chemotherapy regimens. Br J Haematol. 2002;117(4):812–820.
   PubMed Web of Science ®Google Scholar
• Le Deley MC, Rosolen A, Williams DM, et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol. 2010;28(25):3987–3993.
   PubMed Web of Science ®Google Scholar
• Laver JH, Kraveka JM, Hutchison RE, et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol. 2005;23(3):541–547.
   PubMed Web of Science ®Google Scholar
• Alexander S, Kraveka JM, Weitzman S, et al. Advanced stage anaplastic large cell lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: a report from the children’s oncology group. Pediatr Blood Cancer. 2014;61(12):2236–2242.
   PubMed Web of Science ®Google Scholar
• Ceppi F, Ortiz R, Antillón F, et al. Anaplastic large cell lymphoma in Central America: a report from the Central American Association of Pediatric Hematology Oncology (AHOPCA). Pediatr Blood Cancer. 2016;63(1):78–82.
   PubMed Web of Science ®Google Scholar
• Mossé YP. Anaplastic lymphoma kinase as a cancer target in pediatric malignancies. Clin Cancer Res. 2016;22(3):546–552.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Brentuximab vedotin or crizotinib and combination chemotherapy in treating patients with newly diagnosed stage II-IV anaplastic large cell lymphoma. [accessed 2019 Jun 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01979536
   Google Scholar
• Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin’s lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980;7(3):332–339.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay A, Adde M, Magrath I, et al. Result of paediatric non Hodgkin’s lymphoma with intensified short duration chemotherapy: a result from Eastern India. Blood. 2008;112(11):4952–4952.
   Google Scholar
• Banavali SD, Arora B, Vora T, et al. Vinblastine improves outcome in children with anaplastic large cell lymphoma (ALCL) treated with a uniform short duration intensive protocol. SIOP XXXIX meeting Abstracts PJ038. Pediatr Blood Cancer. 2007;49:532.
   Web of Science ®Google Scholar
• Brugières L, Deley MC, Pacquement H, et al. CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood. 1998;92(10):3591–3598.
   PubMed Web of Science ®Google Scholar
• Damm-Welk C, Busch K, Burkhardt B, et al. Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma. Blood. 2007;110(2):670–677.
   PubMed Web of Science ®Google Scholar
• Damm-Welk C, Mussolin L, Zimmermann M, et al. Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. Blood. 2014;123(3):334–337.
   PubMed Web of Science ®Google Scholar
• Mussolin L, Damm-Welk C, Pillon M, et al. Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis. Leukemia. 2013;27(2):416–422.
   PubMed Web of Science ®Google Scholar
• Minard-Colin V, Brugières L, Reiter A, et al. Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead. J Clin Oncol. 2015;33(27):2963–2974.
   PubMed Web of Science ®Google Scholar
• Vaishnavi K, Bansal D, Trehan A, et al. Improving the safety of high-dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin. Pediatr Blood Cancer. 2018;65(12):e27241.
   PubMed Web of Science ®Google Scholar
• Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2004;105(3):948–958.
   PubMed Web of Science ®Google Scholar
• Brugières L, Quartier P, Le Deley MC, et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children–a report from the French Society of Pediatric Oncology. Ann Oncol J Eur Soc Med Oncol. 2000;11(1):53–58.
   PubMed Web of Science ®Google Scholar
• Brugières L, Pacquement H, Le Deley MC, et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol. 2009;27(30):5056–5061.
   PubMed Web of Science ®Google Scholar
• Woessmann W, Zimmermann M, Lenhard M, et al. Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol. 2011;29(22):3065–3071.
   PubMed Web of Science ®Google Scholar
• Strullu M, Thomas C, Le Deley MC, et al. Hematopoietic stem cell transplantation in relapsed ALK + anaplastic large cell lymphoma in children and adolescents: a study on behalf of the SFCE and SFGM-TC. Bone Marrow Transplant. 2015;50(6):795–801.
   PubMed Web of Science ®Google Scholar